Cranbury-based biotech company Amicus Therapeutics has named an experienced pharmaceutical executive as its senior vice president of business and corporate development, it announced Friday.
In his new role, Dr. Michael C. Diem will lead all business and corporate development activities for the company, as well as serving as a member of the senior leadership team. He will report to Chairman and CEO John F. Crowley.
“I am pleased to welcome Dr. Mike Diem to our senior leadership team at Amicus,” Crowley said in a prepared statement. “Mike has an outstanding track record in global business development and corporate strategy within the biotechnology and pharmaceutical industries. Mike will be a key leader for Amicus as we evaluate strategies to enhance our portfolio of leading-edge rare-disease medicines and technologies.”
Diem has a dozen years of experience in pharma and biotech, as well as nearly a decade of work in academic and clinical medicine, Amicus said.
He most recently served as senior vice president of corporate and business development at Aevi Genomic Medicine, and has served in executive roles at AstraZeneca and GSK Rare Diseases.
“I am excited to join the Amicus team during such an important period of growth and globalization,” he said in a statement. “Amicus is well-positioned for further success with a novel rare-disease portfolio, as well as a deep commitment to delivering meaningful benefits for people living with rare diseases.”
